Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse in Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 11, Issue 5, 1997, Pages 845-852

  De Franchis, R ^a   Omodei, P ^a   Ranzi, T ^b   Brignola, C ^c   Rocca, R ^d   Prada, A ^e   Pera, A ^f   Vecchi, M ^g   Del Piano, M ^h   Ferrara, A ^a   Bellolij, C ^a   Piodi, L ^b   Framarin, L ^c   Astegiano, M ^d   Riccioli, F A ^e   Meucci, G ^f  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d GRADENIGO HOSPITAL   (Italy)

^e RHO HOSPITAL   (Italy)

^f MOLINETTE HOSPITAL   (Italy)

^g MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^h Legnano Civil Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE; PLACEBO; STEROID;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COLON DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; ENDOSCOPY; FEMALE; HUMAN; ILEUM DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; REMISSION; TABLET;

EID: 9844254476     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1997.00212.x     Document Type: Article

References (21)

1. Summers RW, Switz DM, Sessions JT, et al. National Co-operative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979; 77: 847-69.
2. Wellmann Vf, Schröder U. New oral preparations for maintenance therapy in Crohn's disease. Can J Gastroenterol 1988; 2(Suppl. A): 71-2(Abstract).
3. International Mesalazine Study Group. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. Aliment Pharmacol Ther 1990; 4: 55-64.
4. Fiasse R. Fontaine F, Vanheuverzwyn R. Prevention of Crohn's disease recurrence after intestinal resection with Eudragit-Lcoated 5-aminosalicylic acid: preliminary results of a 1-year double-blind, placebo controlled study. Gastroenterology 1991; 100: 208(Abstract).
5. Bondesen S, and the Danish 5-ASA Group. Mesalazine (Pentasa) as prophylaxis in Crohn's disease. A multicenter, controlled trial. Scand J Gastroenterol 1991; 26(Suppl. 183): 68(Abstract).
6. Bresci G, Petrucci A, Banti S. 5-AminosalicyIic acid in the prevention of relapses of Crohn's disease in remission: a longterm study. Int J Clin Pharmacol Res 1991; 11: 200-2.
7. Brignola C, lannone P, Pasquali S, et al. Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease. Dig Dis Sei 1992:37:29-32.
8. Prantera C, Pallone F, Brunetti G, et al Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. Gastroenterology 1992; 103: 363-8.
9. Florent CH, Cortot A, Quandale P. et al. Placebo-controlled trial of Claversal (C) in the prevention of early endoscopie relapse after 'curative' resection for Crohn's disease. Gastroenterology 1992; 102: A623(Abstract).
10. Gendre J-P, Mary J-Y, Florent C, et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. Gastroenterology 1993; 104: 435-9.
11. Moschowitz M, Odes S, Bujanover S, et al. A controlled doubleblind multicenter study of the effectiveness of 5-ASA in patients with Crohn's disease in remission. IOIBD Meeting, Bologna, Italy, May 1993(Abstract).
12. Bresci G, Gambardella L. Rindi G, Banti S. Parisi G. Long-term experience with 5-aminosalicylic acid in maintaining remis-sion of inactive Crohn's disease. Ital J Gastroenterol 1994; 26(Suppl. 2): 31(Abstract).
13. Caprilli R, Andreoli A, Capurso L, et al. Oral mesala2ine (5aminosalicylic acid; Asacol) for the prevention of postoperative recurrence of Crohn's disease. Aliment Pharmacol Ther 1994; 8: 35-3.
14. Brignola C, Cottone M, Fera A, et al. Mesalamine in the prevention of endoscopie recurrence after intestinal resection for Crohn's disease. Gastroenterology 1995; 108: 345-9.
15. Arber N, Odes S, Fireman Z, et al A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission. J Clin Gastroenterol 1995; 20: 203-6.
16. McLeod RS, Wolff BG, Steinhart H, et al. Prophylactic Mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology 1995; 109: 404-13.
17. Thomson ABR, Wright JP, Vatn M. et al. Mesalazine (Mesasal/ Claversal) 1.5 g BID daily versus placebo in the maintenance of remission of patients with Crohn's disease. Am J Gastroenterol 1995; 90: 1633(Abstract).
18. de Franchis R, Brignola C, Del Piano M, et al Oral 5 aminosalicylic acid (5-ASA) in the prevention of early relapse of Crohn's disease. Interim analysis of a multicenter double blind randomised placebo-controlled trial. Gastroenterology 1994; 106: A670(Abstract).
19. Messori A, Brignola C, Trallori G, et al Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis. Am J Gastroenterol 1994; 89: 692-8.
20. Steinhart AH, Hemphill D, Greenberg GR. Sulfasalazine and mesalazine for the maintenance therapy of Crohn's Disease: a meta-analysis. Am J Gastroenterol 1994; 89: 2116-24.
21. Travis SP, Jewell DP. Salicylates for inflammatory bowel disease. Baillieres Clin Gastroenterol 1994; 8: 203-31.